Viracta Therapeutics Future Growth
Future criteria checks 2/6
Viracta Therapeutics's earnings are forecast to decline at 0.9% per annum while its annual revenue is expected to grow at 57.6% per year. EPS is expected to grow by 14.7% per annum.
Key information
-0.9%
Earnings growth rate
14.7%
EPS growth rate
Biotechs earnings growth | 30.4% |
Revenue growth rate | 57.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 14 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 30 | -88 | N/A | N/A | 2 |
12/31/2025 | 4 | -89 | N/A | N/A | 2 |
12/31/2024 | N/A | -63 | N/A | N/A | 3 |
3/31/2024 | N/A | -48 | -37 | -36 | N/A |
12/31/2023 | N/A | -51 | -40 | -40 | N/A |
9/30/2023 | N/A | -48 | -38 | -38 | N/A |
6/30/2023 | N/A | -53 | -35 | -34 | N/A |
3/31/2023 | N/A | -51 | -35 | -35 | N/A |
12/31/2022 | N/A | -49 | -36 | -35 | N/A |
9/30/2022 | N/A | -50 | -35 | -35 | N/A |
6/30/2022 | N/A | -47 | -39 | -35 | N/A |
3/31/2022 | N/A | -46 | -37 | -33 | N/A |
12/31/2021 | N/A | -115 | -23 | -19 | N/A |
9/30/2021 | N/A | -110 | -20 | -16 | N/A |
6/30/2021 | N/A | -99 | -13 | -13 | N/A |
3/31/2021 | N/A | -94 | -10 | -10 | N/A |
12/31/2020 | N/A | -19 | -16 | -16 | N/A |
12/31/2019 | N/A | -14 | -10 | -10 | N/A |
12/31/2018 | 1 | -10 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RYI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RYI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RYI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RYI's revenue (57.6% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: RYI's revenue (57.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RYI's Return on Equity is forecast to be high in 3 years time